^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CHO-H01

    i
    Other names: CHO-H01, CHO H01, glyco-engineered anti-CD20 antibody
    Associations

    News

    Trials
    Company:
    Cho Pharma
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Study to Assess Safety and Efficacy of CHO-H01 As a Single Agent/Combined with Lenalidomide in Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=37, Recruiting, Cho Pharma Inc. | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • CHO-H01
    almost2years
    A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=37, Recruiting, Cho Pharma Inc. | N=11 --> 37 | Trial completion date: Feb 2024 --> Jun 2026 | Trial primary completion date: Nov 2023 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    lenalidomide • CHO-H01
    almost3years
    A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=11, Recruiting, Cho Pharma Inc.
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CHO-H01